Compare LDOS & MRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LDOS | MRNA |
|---|---|---|
| Founded | 1969 | 2010 |
| Country | United States | United States |
| Employees | 47000 | N/A |
| Industry | EDP Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 22.5B | 19.7B |
| IPO Year | 2005 | 2018 |
| Metric | LDOS | MRNA |
|---|---|---|
| Price | $156.59 | $52.60 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 13 | 12 |
| Target Price | ★ $207.77 | $34.27 |
| AVG Volume (30 Days) | 789.4K | ★ 5.3M |
| Earning Date | 05-05-2026 | 05-01-2026 |
| Dividend Yield | ★ 1.10% | N/A |
| EPS Growth | 20.82 | ★ 21.77 |
| EPS | ★ 11.14 | N/A |
| Revenue | $17,174,000,000.00 | ★ $19,263,000,000.00 |
| Revenue This Year | $5.59 | $8.74 |
| Revenue Next Year | $4.06 | $16.18 |
| P/E Ratio | $14.03 | ★ N/A |
| Revenue Growth | 3.07 | ★ 4.29 |
| 52 Week Low | $136.91 | $22.28 |
| 52 Week High | $205.77 | $59.55 |
| Indicator | LDOS | MRNA |
|---|---|---|
| Relative Strength Index (RSI) | 39.74 | 55.84 |
| Support Level | $154.52 | $47.61 |
| Resistance Level | $165.66 | $54.94 |
| Average True Range (ATR) | 3.75 | 2.59 |
| MACD | 0.47 | -0.04 |
| Stochastic Oscillator | 47.57 | 73.61 |
Leidos Holdings Inc is a technology, engineering, and science company that provides services and solutions in the defense, intelligence, civil, and health management, both domestically and internationally. The customers of the company includes the U.S. Department of Defense ("DoD"), the U.S. Intelligence Community, the U.S. Department of Homeland Security ("DHS"), the Federal Aviation Administration ("FAA"), the Department of Veterans Affairs ("VA"), and many other U.S. civilian, state and local government agencies, etc. The company is engaged in four reportable segments; National Security & Digital, Health & Civil, Commercial & International and Defense Systems. It provides a wide array of scientific, engineering and technical services and solutions across these reportable segments.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.